The Union for International Cancer Control (UICC) and Pfizer Oncology are proud to announce the names of the five cancer organisations selected to receive additional funding for their SPARC projects which address the needs of MBC patients in their countries and across the world. This funding was committed by Pfizer Oncology as part of the third phase of the SPARC MBC Challenge programme.
The SPARC programme supports MBC projects around the world aimed at addressing patients’ specific needs and reducing the number of women diagnosed at an advanced stage of breast cancer. The projects supported by the SPARC programme focus on the reduction of the gap in patient information and support, raising public awareness to reduce stigma and promote earlier diagnosis, advocating for national policies and strengthening health systems to improve MBC patients’ conditions. Since its launch in 2015, it has directly benefitted more than 14’000 MBC patients worldwide and has reached more than 140’000 people through awareness campaigns.
The projects, which were selected from amongst the 2017 awardees, will continue to work towards improving patient information and patient support gaps in four regions of the world through patient navigation, online learning, digital tools and psychoeducational support:
These projects were selected by the SPARC Selection Advisory Group, a committee of experts in the field of breast cancer chaired by Dr Fatima Cardoso. The committee has evaluated the expected impact and the sustainability of the activities outlined in the top-up proposals.